521 related articles for article (PubMed ID: 27959926)
21. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
22. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
[TBL] [Abstract][Full Text] [Related]
23. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Liu L; Li XR; Hu YH; Zhang J
Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy.
Liao Y; Liao Y; Li J; Xiong J; Fan Y
Sci Rep; 2020 Apr; 10(1):7349. PubMed ID: 32355298
[TBL] [Abstract][Full Text] [Related]
25. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Hatzis C; Pusztai L; Valero V; Booser DJ; Esserman L; Lluch A; Vidaurre T; Holmes F; Souchon E; Wang H; Martin M; Cotrina J; Gomez H; Hubbard R; Chacón JI; Ferrer-Lozano J; Dyer R; Buxton M; Gong Y; Wu Y; Ibrahim N; Andreopoulou E; Ueno NT; Hunt K; Yang W; Nazario A; DeMichele A; O'Shaughnessy J; Hortobagyi GN; Symmans WF
JAMA; 2011 May; 305(18):1873-81. PubMed ID: 21558518
[TBL] [Abstract][Full Text] [Related]
26. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA
Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
Sharma P; López-Tarruella S; García-Saenz JA; Ward C; Connor CS; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Del Monte-Millán M; Gonzalez-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortes J; Fuentes Rivera H; Bretel Morales D; Márquez-Rodas I; Perou CM; Wagner JL; Mammen JM; McGinness MK; Klemp JR; Amin AL; Fabian CJ; Heldstab J; Godwin AK; Jensen RA; Kimler BF; Khan QJ; Martin M
Clin Cancer Res; 2017 Feb; 23(3):649-657. PubMed ID: 27301700
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients).
Eltohamy MI; Badawy OM; El kinaai N; Loay I; Nassar HR; Allam RM; Sakr MA
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3581-3589. PubMed ID: 30583686
[TBL] [Abstract][Full Text] [Related]
29. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
[TBL] [Abstract][Full Text] [Related]
30. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
[TBL] [Abstract][Full Text] [Related]
32. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.
Reinisch M; Huober J; von Minckwitz G; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Schneeweiss A; Rhiem K; Lederer B; Untch M; Nekljudova V V; Loibl S
Breast; 2017 Apr; 32():73-78. PubMed ID: 28063331
[TBL] [Abstract][Full Text] [Related]
33. Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Watanabe Y; Maeda I; Oikawa R; Wu W; Tsuchiya K; Miyoshi Y; Itoh F; Tsugawa K; Ohta T
Genes Cells; 2013 Dec; 18(12):1120-30. PubMed ID: 24581343
[TBL] [Abstract][Full Text] [Related]
34. Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer.
Yoon HK; Kim TH; Park S; Jung H; Quan X; Park SJ; Han J; Lee A
Pathol Res Pract; 2018 Oct; 214(10):1626-1631. PubMed ID: 30139555
[TBL] [Abstract][Full Text] [Related]
35. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
36. Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis.
Bahrin NWS; Matusin SNI; Mustapa A; Huat LZ; Perera S; Hamid MRWHA
Syst Rev; 2024 Apr; 13(1):100. PubMed ID: 38576013
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome.
Powles RL; Wali VB; Li X; Barlow WE; Nahleh Z; Thompson AM; Godwin AK; Hatzis C; Pusztai L
Clin Cancer Res; 2020 Apr; 26(8):1977-1984. PubMed ID: 31919134
[TBL] [Abstract][Full Text] [Related]
38. FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.
Xu YL; Yao R; Li J; Zhou YD; Mao F; Pan B; Sun Q
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1205-1213. PubMed ID: 28493031
[TBL] [Abstract][Full Text] [Related]
39. Objective response of first-line chemotherapy of triple-negative breast cancer translates into survival benefit: an analysis in an independent, prospective clinical trial and a real-world setting.
Li T; Zhu YH; Zhang J; Wang BY; Zhang S; Wang LP; Cao J; Tao ZH; Xie J; Hu XC
Neoplasma; 2020 Nov; 67(6):1400-1408. PubMed ID: 32657608
[TBL] [Abstract][Full Text] [Related]
40. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
Ignatov T; Poehlmann A; Ignatov A; Schinlauer A; Costa SD; Roessner A; Kalinski T; Bischoff J
Breast Cancer Res Treat; 2013 Sep; 141(2):205-12. PubMed ID: 24026861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
